Susquehanna Fundamental Investments LLC Purchases Shares of 104,094 AtriCure, Inc. (NASDAQ:ATRC)

Susquehanna Fundamental Investments LLC acquired a new stake in AtriCure, Inc. (NASDAQ:ATRC - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 104,094 shares of the medical device company's stock, valued at approximately $3,181,000. Susquehanna Fundamental Investments LLC owned approximately 0.21% of AtriCure at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Adage Capital Partners GP L.L.C. acquired a new stake in shares of AtriCure during the fourth quarter worth $9,168,000. Kennedy Capital Management LLC increased its stake in AtriCure by 29.8% in the 4th quarter. Kennedy Capital Management LLC now owns 752,580 shares of the medical device company's stock worth $22,999,000 after purchasing an additional 172,648 shares in the last quarter. Marshall Wace LLP raised its holdings in AtriCure by 37.1% during the 4th quarter. Marshall Wace LLP now owns 619,166 shares of the medical device company's stock worth $18,922,000 after buying an additional 167,476 shares during the period. Oberweis Asset Management Inc. acquired a new stake in AtriCure during the 4th quarter worth about $4,630,000. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of AtriCure by 24.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 700,212 shares of the medical device company's stock worth $21,398,000 after buying an additional 136,015 shares during the period. Institutional investors and hedge funds own 99.11% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on ATRC shares. Oppenheimer boosted their price target on shares of AtriCure from $36.00 to $45.00 and gave the company an "outperform" rating in a report on Thursday, February 13th. Stifel Nicolaus increased their target price on AtriCure from $36.00 to $48.00 and gave the company a "buy" rating in a report on Thursday, February 13th. Needham & Company LLC lowered their price target on AtriCure from $51.00 to $44.00 and set a "buy" rating on the stock in a report on Wednesday. BTIG Research reissued a "buy" rating on shares of AtriCure in a research report on Thursday, March 27th. Finally, UBS Group decreased their price objective on AtriCure from $60.00 to $58.00 and set a "buy" rating for the company in a research report on Wednesday. One analyst has rated the stock with a hold rating and nine have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $50.67.

AtriCure Stock Up 2.5 %

NASDAQ ATRC traded up $0.73 on Friday, reaching $30.02. The stock had a trading volume of 855,143 shares, compared to its average volume of 654,587. The company has a market capitalization of $1.49 billion, a price-to-earnings ratio of -31.60 and a beta of 1.65. The business has a 50 day moving average price of $33.57 and a 200 day moving average price of $34.72. The company has a current ratio of 3.65, a quick ratio of 2.62 and a debt-to-equity ratio of 0.13. AtriCure, Inc. has a 1 year low of $18.94 and a 1 year high of $43.11.

AtriCure (NASDAQ:ATRC - Get Free Report) last announced its quarterly earnings results on Tuesday, April 29th. The medical device company reported ($0.14) earnings per share for the quarter, topping analysts' consensus estimates of ($0.25) by $0.11. The company had revenue of $123.62 million during the quarter, compared to analysts' expectations of $122.92 million. AtriCure had a negative return on equity of 6.80% and a negative net margin of 9.61%. The business's quarterly revenue was up 13.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.28) earnings per share. On average, analysts forecast that AtriCure, Inc. will post -0.6 EPS for the current fiscal year.

Insider Buying and Selling

In other AtriCure news, Director Karen Prange sold 6,100 shares of AtriCure stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $38.12, for a total value of $232,532.00. Following the transaction, the director now directly owns 17,828 shares of the company's stock, valued at $679,603.36. The trade was a 25.49 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 3.50% of the company's stock.

About AtriCure

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.